Profit Financial Performance Profitability Earnings Reports Market Performance Profit Margins Penalties Automotive Sector Fiscal Reports Donations
Phase-3 results demonstrated a 20% higher cure rate over meropenem with forecasts valuing the drug at $9 billion globally